Annovis Bio’s (ANVS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Annovis Bio (NYSE:ANVS) in a research note published on Wednesday, Benzinga reports. They currently have a $23.00 target price on the stock.

A number of other research analysts have also issued reports on the stock. Rodman & Renshaw began coverage on shares of Annovis Bio in a research note on Tuesday, June 4th. They set a buy rating and a $67.00 price target on the stock. Canaccord Genuity Group cut their price target on shares of Annovis Bio from $36.00 to $26.00 and set a buy rating on the stock in a research note on Tuesday, April 30th. Finally, Brookline Capital Management lowered shares of Annovis Bio from a buy rating to a hold rating and set a $9.00 price target on the stock. in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $32.20.

Annovis Bio Stock Down 2.7 %

NYSE ANVS opened at $5.85 on Wednesday. The firm has a market cap of $65.34 million, a PE ratio of -1.02 and a beta of 1.78. The company has a 50 day moving average price of $8.20 and a 200 day moving average price of $10.21. Annovis Bio has a 52 week low of $4.79 and a 52 week high of $22.49.

Annovis Bio (NYSE:ANVS) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.15. On average, equities research analysts anticipate that Annovis Bio will post -2.46 earnings per share for the current fiscal year.

Institutional Trading of Annovis Bio

Large investors have recently made changes to their positions in the business. Private Trust Co. NA purchased a new stake in shares of Annovis Bio in the 4th quarter valued at $56,000. Cetera Advisors LLC purchased a new stake in shares of Annovis Bio in the 1st quarter valued at $122,000. Greenwich Wealth Management LLC purchased a new stake in shares of Annovis Bio in the 4th quarter valued at $192,000. Wealthspire Advisors LLC boosted its holdings in shares of Annovis Bio by 9.9% in the 4th quarter. Wealthspire Advisors LLC now owns 10,990 shares of the company’s stock valued at $206,000 after acquiring an additional 990 shares during the last quarter. Finally, Redmond Asset Management LLC boosted its holdings in shares of Annovis Bio by 6.1% in the 1st quarter. Redmond Asset Management LLC now owns 36,157 shares of the company’s stock valued at $430,000 after acquiring an additional 2,077 shares during the last quarter. 15.83% of the stock is owned by hedge funds and other institutional investors.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.